• Explore /
  • Poster
  • / Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers.

Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers.

Abstract Video & Slides Poster

Authors

Siqing Fu

Siqing Fu

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Siqing Fu , Lisle Nabell , Alexander T. Pearson , Rom Leidner , Douglas Adkins , Marshall R. Posner , Jorge J. Nieva , Debra L. Richardson , Agustin Pimentel , Sanjay Goel , Stuart J. Wong , Alan Loh Ho , Ari Rosenberg , Matthew H. Taylor , Raghad Abdul-Karim , Corinne Iacobucci , Xiaoping Qing , Kia Katchar , Katia Schlienger , David G. Pfister

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Vaccines

Clinical Trial Registration Number

NCT04180215

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2517)

DOI

10.1200/JCO.2022.40.16_suppl.2517

Abstract #

2517

Poster Bd #

173

Abstract Disclosures

Similar Posters

First Author: Bailey Fabiny Garb

First Author: Chris M. Black

First Author: Sidharth Puram

First Author: Jared Weiss